New Reg-A Investment Opportunity

A: It is anticipated that a distinct approval will be mandated for every novel pairing of a therapeutic agent with the Magnetodrones. This adheres to the standard FDA requirement, where each new formulation or combination necessitates specific approval within the realm of medical technologies.

A: Starpax Therapy is designed to address solid tumors that represent 90% of cancer and 89% of deaths. In this context, Starpax aspires to extend the application of its technology to encompass all potential indications.. We envision a promising future for Starpax’s innovative modality, viewing it as a transformative industry breakthrough with significant positive societal impacts.

A: In technical terms, yes, it is feasible. However, as is customary with many medical technologies, the technology initially requires approval for use in adults. After obtaining approval for adult use, Starpax intends to proceed with further clinical development to seek approval for application in children.

A: Indeed, the Starpax Platform is designed with the potential to address cranial and brain cancers. However, this necessitates further interventional assessments and development to confirm the appropriate procedures. Starpax is committed to commencing this work after the beginning of the forthcoming clinical trials.

A: In stark contrast to the majority of new cancer treatments in development that may never attain first-line status, Starpax firmly believes that its technology possesses the attributes necessary to become a first-line treatment. This conviction is rooted in several key factors:

1. Starpax technology is designed to circumvent the toxicity associated with systemic treatments by containing the drug within the tumor with the magnetic vectors of the PolarTrak.
2. It offers a non-invasive approach: simple intratumoral 10-minute injection of the Magnetodrones being done in an outpatient facility.
3. The potential exists for preserving tissue and organ functions, mitigating risks associated with radiation therapy and surgical interventions.
4. Starpax is anticipated to provide superior efficacy by delivering the drug throughout the tumor volume at significantly higher doses than systemic treatments.
5. It specifically targets the often hard-to-reach hypoxic zones, which are responsible for metastasis and recurrence.
6. Additionally, it acts as an immune trigger, further enhancing its therapeutic potential.

(For additional information: https://starpaxbiopharma.com/technology/#technology_sec_2)

A: Patient recruitment for the clinical trials can only commence once authorization is granted by regulatory authorities. Unfortunately, we are not allowed to maintain a waiting list, confirm trials exact commencement date, or provide information on patient eligibility criteria at this time. We recommend consulting with your oncologist to explore currently available treatment options and ongoing clinical studies that are actively enrolling patients. You can access a specialized website for this purpose at https://clinicaltrials.gov/ct2/home. Each clinical study has distinct inclusion criteria, so it is essential to have a discussion with your oncologist to determine whether a specific study might be a suitable option for you. As for Starpax, announcements and communications will be disseminated to the oncologist community in the future. In the meantime, it is crucial not to delay consulting with your oncologist regarding your treatment options.